Tailoring B cell depletion therapy in MS according to memory B cell monitoring
暂无分享,去创建一个
M. Sormani | M. Inglese | L. Roccatagliata | G. Mancardi | A. Uccelli | C. Solaro | A. Laroni | N. Bruschi | G. Boffa | F. Bovis | G. Novi | F. Tazza | C. Lapucci | M. Cellerino | E. Capello | G. Pesce | S. Fabbri | P. Gazzola | D. Currò | Ilaria Maietta
[1] A. Bar-Or,et al. P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions , 2020, Clinical Neurophysiology.
[2] M. Sormani,et al. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. , 2019, Multiple sclerosis and related disorders.
[3] Jae-Won Hyun,et al. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder , 2019, Neurochemistry International.
[4] M. Sormani,et al. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience , 2019, Multiple sclerosis.
[5] S. Berntsson,et al. Rapidly increasing off‐label use of rituximab in multiple sclerosis in Sweden — Outlier or predecessor? , 2018, Acta neurologica Scandinavica.
[6] K. Schmierer,et al. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis , 2017, EBioMedicine.
[7] A. Traboulsee,et al. Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.
[8] Peter Sundström,et al. Rituximab in multiple sclerosis , 2016, Neurology.
[9] J. Joo,et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. , 2015, JAMA neurology.
[10] Su-Hyun Kim,et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. , 2011, Archives of neurology.